Impax Laboratories Inc  

(Public, NASDAQ:IPXL)   Watch this stock  
Find more results for IPXL
33.35
-0.82 (-2.40%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 32.59 - 34.38
52 week 29.66 - 51.42
Open 34.16
Vol / Avg. 0.00/582,475.00
Mkt cap 2.41B
P/E 62.35
Div/yield     -
EPS 0.53
Shares 73.89M
Beta 1.22
Inst. own 94%
May 17, 2016
Impax Laboratories Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
May 11, 2016
Impax Laboratories Inc Annual Shareholders Meeting (Estimated) - 12:00PM EDT - Add to calendar
May 10, 2016
Q1 2016 Impax Laboratories Inc Earnings Release - 9:30AM EDT - Add to calendar
May 10, 2016
Q1 2016 Impax Laboratories Inc Earnings Call - 8:30AM EDT - Add to calendar
Mar 17, 2016
Impax Laboratories Inc at Barclays Global Healthcare Conference - Webcast
Mar 7, 2016
Impax Laboratories Inc at Raymond James Institutional Investors Conference - Webcast
Feb 22, 2016
Q4 2015 Impax Laboratories Inc Earnings Release
Feb 22, 2016
Q4 2015 Impax Laboratories Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 4.05% 4.53%
Operating margin 10.92% 6.12%
EBITD margin - 18.18%
Return on average assets 2.34% 2.60%
Return on average equity 4.38% 4.00%
Employees 1,290 -
CDP Score - -

Address

30831 Huntwood Ave
HAYWARD, CA 94544-7003
United States - Map
+1-510-2406000 (Phone)
+1-510-2406096 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Specialty Pharma is also engaged in the sale and distribution of Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Officers and directors

Robert L. Burr Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
G. Frederick Wilkinson President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Bryan M. Reasons Chief Financial Officer, Senior Vice President - Finance
Age: 47
Bio & Compensation  - Reuters
Michael J. Nestor President - Impax Pharmaceutical Division
Age: 62
Bio & Compensation  - Reuters
Deborah Penza Senior Vice President, Chief Compliance Officer
Bio & Compensation  - Reuters
Mark A. Schlossberg Esq. Senior Vice President, General Counsel, Corporate Secretary
Age: 54
Bio & Compensation  - Reuters
Donna Marie Hughes Senior Vice President of Human Resources
Bio & Compensation  - Reuters
Jeffrey D Nornhold Senior Vice President - Technical Operations
Age: 49
Bio & Compensation  - Reuters
Janet S. Vergis Director
Age: 51
Bio & Compensation  - Reuters
Leslie Z. Benet Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters